From Wikipedia,
the free encyclopedia.
Biogen Idec Inc. (NASDAQ:BIIB)
is a
pharmaceutical company
specializing in drugs for
autoimmune disorders and
cancer. The company was formed
in
2003 by the
merger of
Cambridge, Massachusetts-based
Biogen and
San Diego, California-based
Idec Pharmaceuticals.
Biogen Idec is a member of the
S&P 500,
S&P 1500, and
Nasdaq 100. It employs a
little over 4,000 employees.
Locations of operation
Biogen Idec is headquartered in
Kendall Square in Cambridge,
Massachusetts, and operates
research and development
facilities in Cambridge and San
Diego. Biogen Idec operates
manufacturing facilities in
Kendall Square,
Research Triangle Park, North
Carolina, and Hoofddorp,
Netherlands. The company is also
building a Large Scale
Manufacturing plant in Hillerod,
Denmark, which is expected to go
online in 2008.
Biogen Idec maintains its
international headquarters in
Zug,
Switzerland, and operates an
International regulatory &
clinical center of excellence in
Maidenhead, UK. In Europe, Biogen
Idec has direct commercial
affiliates in
Germany,
France, Spain/Portugal,
UK/Ireland,
the
Benelux,
Sweden,
Denmark,
Norway,
Finland, and
Austria. In
Italy and in
Switzerland, Biogen Idec
markets its products through two
joint venture companies set up
with the privately held Italian
company Dompe Biotec. Biogen Idec
also has offices in
Canada,
Australia, and
Japan.
Management
BIIB is managed day-to-day by
an executive group composed of
nine officers. As customary for a
publicly-traded company, BIIB is
also overseen by a board of
directors that votes on important
company decisions. The executive
chairman and chief executive
officer both hold positions on the
board of directors.
Executive Chairman:
William H. Rastetter, Ph.D.
President, Chief Executive
Officer: James C. Mullen
Executive Vice President,
Development: Burt A. Adelman
Executive Vice President, New
Ventures: John M. Dunn
Executive Vice President,
Research: Michael Gilman
Executive Vice President,
Finance and Chief Financial
Officer: Peter N. Kellogg
Executive Vice President,
Corporate Strategy and
Communication: Connie L.
Matsui
Executive Vice President, Human
Resources: Craig Eric Schneier,
Ph.D.
Executive Vice President,
Business Development: Mark
Wiggins
Directors: Alan Belzer,
Lawrence C. Best, Alan B.
Glassberg, Mary L. Good, Thomas F.
Keller, Robert W. Pangia, Bruce R.
Ross, The Honorable Lynn Schenk,
Phillip A. Sharp, Willian D. Young
Competitors
Biogen Idec's principal
competitors include
Teva,
Serono, and Schering AG/Berlex.
As of 2004, Biogen Idec
derives most of its income from
sales of
multiple sclerosis treatment
Avonex and from partnership
royalties on Rituxan from
Genentech, which markets
Rituxan) in the US. Roche
markets Rituxan outside the US as
Mabthera.
Biogen Idec Inc. (NASDAQ:BIIB)
is a
biotechnology company
specializing in drugs for
autoimmune disorders and
cancer. The company was formed
in
2003 by the
merger of
Cambridge, Massachusetts-based
Biogen and
San Diego, California-based
Idec Pharmaceuticals.
Locations of operation
Biogen Idec is headquartered in
Kendall Square in Cambridge,
Massachusetts, and operates
research and development
facilities in Cambridge and San
Diego. Biogen Idec operates
manufacturing facilities in
Kendall Square,
Research Triangle Park, North
Carolina, and Hoofddorp,
Netherlands. The company is also
building a Large Scale
Manufacturing plant in Hillerod,
Denmark, which is expected to go
online in 2008.
Biogen Idec maintains its
international headquarters in
Zug,
Switzerland, and operates an
International regulatory &
clinical center of excellence in
Maidenhead, UK. In Europe, Biogen
Idec has direct commercial
affiliates in
Germany,
France,
Spain,Portugal,
UK/Ireland,
the
Benelux,
Sweden,
Denmark,
Norway,
Finland, and
Austria. In
Italy and in
Switzerland, Biogen Idec
markets its products through two
joint venture companies set up
with the privately held Italian
company Dompe Biotec. Biogen Idec
also has offices in
Canada,
Australia, and
Japan.
Management
BIIB is managed day-to-day by
an executive group composed of
nine officers. As customary for a
publically-traded company, BIIB is
also overseen by a board of
directors that votes on important
company decisions. The executive
chairman and chief executive
officer both hold positions on the
board of directors.
Executive Chairman:
William H. Rastetter, Ph.D.
President, Chief Executive
Officer: James C. Mullen
Executive Vice President,
Development: Burt A. Adelman
Executive Vice President, New
Ventures: John M. Dunn
Executive Vice President,
Research: Michael Gilman
Executive Vice President,
Finance and Chief Financial
Officer: Peter N. Kellogg
Executive Vice President,
Corporate Strategy and
Communication: Connie L.
Matsui
Executive Vice President, Human
Resources: Craig Eric Schneier,
Ph.D.
Executive Vice President,
Business Development: Mark
Wiggins
Directors: Alan Belzer,
Lawrence C. Best, Alan B.
Glassberg, Mary L. Good, Thomas F.
Keller, Robert W. Pangia, Bruce R.
Ross, The Honorable Lynn Schenk,
Phillip A. Sharp, Willian D. Young
Competitors
Biogen Idec's major competitors
in the Multiple Sclerosis
therapeutic area are
Serono,
Teva, and Schering AG.
As of 2005, Biogen Idec
derives most of its income from
sales of
multiple sclerosis treatment
Avonex, and from partnership
royalties from its product
Rituxan, market in the US by
Genentech. Outside of the US,
Rituxan is named Mabthera and is
marketed by Roche.
News
On
February 28,
2005, Biogen Idec and
marketing partner
Elan Pharmaceuticals
voluntarily suspended marketing of
their product TYSABRI (natalizumab),
and also suspended dosing in all
ongoing clinical trials. TYSABRI
had been approved in the US in
November 2004 for treatment of
patients with relapsing remitting
multiple sclerosis (MS).
The two companies announced the
suspension after two participants
involved in one study were
diagnosed with a severe brain
condition, progressive multifocal
leukoencephalopathy (PML),
after two years of combination
therapy with AVONEX, another
Biogen Idec product. One of those
two patients died. Subsequently,
another patient who had previously
died in a separate clinical trial
of TYSABRI in patients with
Crohns Disease was
re-evaluated as having had PML. In
total, 3 cases of PML were
identified, of which 2 cases were
fatal.
http://en.wikinews.org/wiki/Elan%3B_Biogen_withdraw_MS_drug_after_death
